News from PipelinereviewFollowNews from PipelinereviewStay current with all the latest and breaking news from Pipelinereview. Compare headlines and media bias behind news outlets on stories breaking today.Ground News has come across 496 headlines reported on by Pipelinereview during the past 3 months. Ground News rates Pipelinereview’s media bias as . . Ground News is unable to assign a bias rating and does not have ratings available from Ad Fontes Media, All Sides, and Media Bias/Fact Check. Pipelinereview’s factuality rating is Unknown. Ground News calculates this rating using a combination of the fact and reliability ratings from Ad Fontes Media and Media Bias/Fact Check.Follow Stay current with all the latest and breaking news from Pipelinereview. Compare headlines and media bias behind news outlets on stories breaking today. Ground News has come across 496 headlines reported on by Pipelinereview during the past 3 months. Ground News rates Pipelinereview’s media bias as . . Ground News is unable to assign a bias rating and does not have ratings available from Ad Fontes Media, All Sides, and Media Bias/Fact Check. Pipelinereview’s factuality rating is Unknown. Ground News calculates this rating using a combination of the fact and reliability ratings from Ad Fontes Media and Media Bias/Fact Check. Information about PipelinereviewWhere is Pipelinereview located?Pipelinereview's WebsiteMedia Bias RatingsDo you diasgree? Edit biasLearn more about Media Bias Ratings.FactualityAverage Factuality Rating: UnknownLearn more about Factuality Ratings.Top Pipelinereview NewsAlzheimerLeqembi Okayed for Subset of Early Alzheimer’s Patients100% Right coverage: 5 sourcesThe European Medicines Agency’s (EMA’s) Committee for Medicinal Products for Human Use (CHMP) has recommended granting marketing authorization for Leqembi (lecanemab) to treat mild cognitive impairment and early Alzheimer’s disease, following a re-examination of the clinical data. The recommendation is only for patients who have one or no copies of the apolipoprotein E4 (APOE4) gene […]See the StoryFDA · United StatesFDA Approves First Menin Inhibitor for Acute LeukemiaCoverage: 2 sourcesThe FDA granted full approval to the menin inhibitor revumenib (Revuforj) for adults and children 1 year and older withSee the StoryUnited States · United StatesUS FDA approves PTC Therapeutics’ gene therapy for ultra-rare disorder100% Center coverage: 1 sources(Reuters) – The U.S. Food and Drug Administration approved PTC Therapeutics’ gene therapy that is administered directly in the brain to treat a potential fatal enzyme deficiency disorder, the company said on Wednesday. (Reporting by Sriparna Roy, Leroy Leo and Christy Santhosh in Bengaluru; Editing by Maju Samuel)See the StoryLatest News StoriesTopics Most Covered by pipelinereviewVaccinesAstraZenecaMerckMedicalPfizerVaccinesAstraZenecaMerckSources Covering Similar Topicsstocktitan.netClinical Trials Arenapressreach.comPharmacy TimesEndpoints Newsstocktitan.netClinical Trials Arenapressreach.comSuggest a sourceLooking for a source we don't already have? Suggest one here.You've scrolled to the bottom of the feed, there are no more stories.
